Tibor Schuster

Tibor Schuster

Auto-generated profile, based on publicly available information

Tibor Schuster

Department of Family Medicine, McGill University, Montreal, Quebec, Canada

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2024 in Journal of Medical Internet Research
Verified
Journal Article
Open access
MLMoustafa Laymouna
Moustafa Laymouna
BLBertrand Lebouche
Bertrand Lebouche
DLDavid Lessard
David Lessard
TSTibor Schuster
Tibor Schuster
KEKim Engler
Kim Engler
Bertrand LebouchéBertrand Lebouché
Bertrand Lebouché
Background: Chatbots, or conversational agents, have emerged as significant tools in health care, driven by advancements in artificial intelligence and digital technology. These programs are designed to simulate human conversations, addressing various health care needs. However, no comprehensive synthesis of health care chatbots’ roles, users, benefits, and limitations is available to inform future research and application in the field. Objective: This review aims to describe health care chatbots’ characteristics, focusing on their diverse roles in the health care pathway, user groups, benefits, and limitations. Methods: A rapid review of published literature from 2017 to 2023 was performed with a search strategy developed in collaboration with a health sciences librarian and implemented in the MEDLINE and Embase databases. Primary research studies reporting on chatbot roles or benefits in health care were included. Two reviewers dual-screened the search results. Extracted data on chatbot roles, users, benefits, and limitations were subjected to content analysis. Results: The review categorized chatbot roles into 2 themes: delivery of remote health services, including patient support, care management, education, skills building, and health behavior promotion, and provision of administrative assistance to health care providers. User groups spanned across patients with chronic conditions as well as patients with cancer; individuals focused on lifestyle improvements; and various demographic groups such as women, families, and older adults. Professionals and students in health care also emerged as significant users, alongside groups seeking mental health support, behavioral change, and educational enhancement. The benefits of health care chatbots were also classified into 2 themes: improvement of health care quality and efficiency and cost-effectiveness in health care delivery. The identified limitations encompassed ethical challenges, medicolegal and safety concerns, technical difficulties, user experience issues, and societal and economic impacts. Conclusions: Health care chatbots offer a wide spectrum of applications, potentially impacting various aspects of health care. While they are promising tools for improving health care efficiency and quality, their integration into the health care system must be approached with consideration of their limitations to ensure optimal, safe, and equitable use.


1 April 2020 in Journal of Affective Disorders
Verified
Journal Article
Closed access
SPSvetlana Puzhko
Svetlana Puzhko
SASarah A.E. Aboushawareb
Sarah A.E. Aboushawareb
IKIrina Kudrina
Irina Kudrina
TSTibor Schuster
Tibor Schuster
TBTracie A. Barnett
Tracie A. Barnett
GBGillian Bartlett
Gillian Bartlett

4 December 2015 in The International Journal of Biostatistics
Verified
Journal Article
Open access
PDF file
MPMenglan Pang
Menglan Pang
TSTibor Schuster
Tibor Schuster
KFKristian B. Filion
Kristian B. Filion
MSMireille E. Schnitzer
Mireille E. Schnitzer
MEMaria Eberg
Maria Eberg
RPRobert W. Platt
Robert W. Platt
Inverse probability of treatment weighting (IPW) and targeted maximum likelihood estimation (TMLE) are relatively new methods proposed for estimating marginal causal effects. TMLE is doubly robust, yielding consistent estimators even under misspecification of either the treatment or the outcome model. While IPW methods are known to be sensitive to near violations of the practical positivity assumption (e. g., in the case of data sparsity), the consequences of this violation in the TMLE framework for binary outcomes have been less widely investigated. As near practical positivity violations are particularly likely in high-dimensional covariate settings, a better understanding of the performance of TMLE is of particular interest for pharmcoepidemiological studies using large databases. Using plasmode and Monte-Carlo simulation studies, we evaluated the performance of TMLE compared to that of IPW estimators based on a point-exposure cohort study of the marginal causal effect of post-myocardial infarction statin use on the 1-year risk of all-cause mortality from the Clinical Practice Research Datalink. A variety of treatment model specifications were considered, inducing different degrees of near practical non-positivity. Our simulation study showed that the performance of the TMLE and IPW estimators were comparable when the dimension of the fitted treatment model was small to moderate; however, they differed when a large number of covariates was considered. When a rich outcome model was included in the TMLE, estimators were unbiased. In some cases, we found irregular bias and large standard errors with both methods even with a correctly specified high-dimensional treatment model. The IPW estimator showed a slightly better root MSE with high-dimensional treatment model specifications in our simulation setting. In conclusion, for estimation of the marginal expectation of the outcome under a fixed treatment, TMLE and IPW estimators employing the same treatment model specification may perform differently due to differential sensitivity to practical positivity violations; however, TMLE, being doubly robust, shows improved performance with richer specifications of the outcome model. Although TMLE is appealing for its double robustness property, such violations in a high-dimensional covariate setting are problematic for both methods.

15 June 2013 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
HLHans-Joachim Lück
Hans-Joachim Lück
ABAndreas Du Bois
Andreas Du Bois
SLSibylle Loibl
Sibylle Loibl
ISIris Schrader
Iris Schrader
JHJens Bodo Huober
Jens Bodo Huober
GMGunter von Minckwitz
Gunter von Minckwitz

10 April 2015 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Closed access
PDF file
TSTibor Schuster
Tibor Schuster
MPMenglan Pang
Menglan Pang
RPRobert W. Platt
Robert W. Platt